Safety of Nifedipine GITS in Stable Angina: The ACTION Trial
Authors:
- on behalf of the ACTION InvestigatorsOIon behalf of the ACTION Investigators
- Bridget-Anne KirwanBKBridget-Anne Kirwan
- Zoltán VokóZVZoltán Vokó
- 1 February 2006
- journal article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 20 (1) , 45-54
Abstract
Aim: We describe the safety profile of nifedipine GITS as assessed from adverse events reported in the ACTION trial in which 7,665 patients with stable, symptomatic coronary artery disease were randomly assigned nifedipine GITS or placebo and followed for a mean of 4.9 years. Methods: All adverse events were coded using the COSTART coding dictionary. The incidence rate for each event was calculated as the number of patients with the event concerned divided by the total time ‘at risk’. Hazard ratios comparing nifedipine with placebo and their 95% confidence intervals were obtained by Cox proportional-hazards analysis. Results: As reported previously, nifedipine significantly reduced the incidence of cardiovascular events and procedures [hazard ratio (HR) 0.89, 95% confidence interval (CI) 0.83–0.95]. Apart from the known side effects of nifedipine, which include peripheral oedema, vasodilatation, hypotension, asthenia, constipation, leg cramps, non-specific respiratory complaints, impotence and polyuria, and which were reported more frequently in patients assigned nifedipine, the incidence rates of most other adverse events were similar. There were no differences in the occurrence of gastrointestinal haemorrhage, myocardial infarction and suicide. The rate of occurrence of death or new cancer excluding non-melanoma skin cancer for patients with no history of cancer at baseline was 2.53/100 patient years for patients assigned nifedipine and 2.37/100 patient years for patients assigned placebo (HR 1.06, 95% CI 0.93–1.22). Conclusion: Overall nifedipine GITS was well tolerated by patients with stable symptomatic angina.Keywords
This publication has 41 references indexed in Scilit:
- What Have We Learned From the Calcium Channel Blocker Controversy?Circulation, 1998
- Conflict of Interest in the Debate over Calcium-Channel AntagonistsNew England Journal of Medicine, 1998
- Calcium-antagonist controversy: the long and short of it?The Lancet, 1997
- EditorialThe American Journal of Cardiology, 1996
- The calcium antagonist controversy; implications beyond drug prescriptionEuropean Heart Journal, 1996
- Do calcium antagonists cause myocardial infarction?The American Journal of Cardiology, 1996
- Spinning the risks and benefits of calcium antagonistsThe Lancet, 1995
- NifedipineCirculation, 1995
- Nifedipine and MortalityCirculation, 1995
- The Calcium Channel Blocker ScareCirculation, 1995